Equities Analysts Offer Predictions for NBIX FY2024 Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Stock analysts at Cantor Fitzgerald decreased their FY2024 EPS estimates for Neurocrine Biosciences in a report released on Thursday, October 31st. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings per share of $4.15 for the year, down from their previous forecast of $4.30. Cantor Fitzgerald currently has a “Overweight” rating and a $155.00 target price on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.31 per share.

Other equities analysts have also recently issued reports about the company. Jefferies Financial Group lifted their price target on Neurocrine Biosciences from $177.00 to $189.00 and gave the company a “buy” rating in a research report on Monday, August 19th. Piper Sandler upgraded Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and upped their price target for the company from $131.00 to $159.00 in a research report on Thursday, August 29th. Raymond James reissued an “outperform” rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Robert W. Baird boosted their price objective on shares of Neurocrine Biosciences from $157.00 to $180.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Finally, Guggenheim increased their target price on shares of Neurocrine Biosciences from $170.00 to $180.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Five research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $163.91.

Neurocrine Biosciences Trading Down 1.4 %

Neurocrine Biosciences stock opened at $120.53 on Monday. The firm has a 50 day simple moving average of $119.13 and a 200 day simple moving average of $133.41. Neurocrine Biosciences has a 1-year low of $103.63 and a 1-year high of $157.98. The firm has a market capitalization of $12.20 billion, a price-to-earnings ratio of 32.31 and a beta of 0.35.

Insiders Place Their Bets

In other news, Director William H. Rastetter sold 14,250 shares of the company’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $146.69, for a total value of $2,090,332.50. Following the completion of the sale, the director now owns 37,491 shares of the company’s stock, valued at approximately $5,499,554.79. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director William H. Rastetter sold 14,250 shares of the business’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $146.69, for a total value of $2,090,332.50. Following the completion of the sale, the director now owns 37,491 shares of the company’s stock, valued at approximately $5,499,554.79. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Gary A. Lyons sold 11,570 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $150.43, for a total value of $1,740,475.10. Following the sale, the director now owns 119,047 shares of the company’s stock, valued at $17,908,240.21. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 47,063 shares of company stock valued at $7,023,330. 4.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. RFP Financial Group LLC grew its holdings in Neurocrine Biosciences by 346.5% in the 1st quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock worth $26,000 after acquiring an additional 149 shares during the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in shares of Neurocrine Biosciences in the second quarter worth about $28,000. Innealta Capital LLC purchased a new position in Neurocrine Biosciences during the 2nd quarter valued at about $30,000. New Covenant Trust Company N.A. bought a new position in Neurocrine Biosciences during the 1st quarter valued at approximately $32,000. Finally, EdgeRock Capital LLC bought a new position in Neurocrine Biosciences during the 2nd quarter valued at approximately $35,000. Institutional investors own 92.59% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.